US FDA grants approval to Aurobindo Pharma's osteoporosis drug risedronate
The approved product has an estimated market size of $ 113 million for the twelve months ending October 2015, according to IMS
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market risedronate sodium tablets (5 mg, 30 mg and 35 mg). “This approval is an extension of tentative approval received on October 10, 2012. This product is ready for launch,” said Aurobindo Pharma in a press statement .
Risedronate sodium tablet, a generic version of Warner Chilcott’s Actonel, is used in the treatment of osteoporosis. The approved product has an estimated market size of $ 113 million for the twelve months ending October 2015, according to IMS.
Risedronate sodium tablet, a generic version of Warner Chilcott’s Actonel, is used in the treatment of osteoporosis. The approved product has an estimated market size of $ 113 million for the twelve months ending October 2015, according to IMS.